Health spending at state’s top insurer surged 12%, led by GLP-1s
State House News Service reports on a Health Affairs study, co-authored by Harvard and Blue Cross Blue Shield of Massachusetts experts, analysing the insurer's claims data. Spending growth reached 11.8% in fiscal 2025, up from 1.2% in calendar year 2019. GLP-1 drug spending rose about 84%, versus 9.6% for other retail drugs. Researchers also cite rising coding intensity and say price growth was not a major contributor.
Why it matters: Relevant to clinicians and patients following GLP-1 coverage and drug-cost debates; the study covers one Massachusetts insurer's commercial members only.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to yahoo.com. October 7, 2026.